Store below 30C away from light and moisture, and keep out of the sight and reach of children
Access has been a real issue for injectable GLP-1 medications due to high demand
What happens during this transition: Your metabolism slows down as you lose lean muscle mass Visceral fat (the deep abdominal fat around your organs) increases significantly Your risk of heart disease rises Glucose control can become more challenging, increasing diabetes risk Bone density starts to decline Weight gain during menopause is normal (but that doesnt make It easy) If youve been gaining weight during perimenopause or menopause, youre definitely not alone
Important safety considerations include a boxed warning for risk of thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), and risks of pancreatitis, gallbladder disease, acute kidney injury with dehydration, and diabetic retinopathy complications with semaglutide
This is not the ideal situation as there are risks associated with taking another medication however, in the short term while your body adapts to the GLP-1 RA, it can certainly be considered
1 Weight loss effect of semaglutide on MASH resolution (a), steatosis improvement (b), hepatocyte ballooning (c) and liver fibrosis improvement (d)